TCH与TAC新辅助化疗在HER-2过表达乳腺癌中的疗效观察

陈伟财; 何劲松; 吴恢升; 王敏; 宋淑芬; 王先明

doi:10.3969/j.issn.1000-8179.20131484

TCH与TAC新辅助化疗在HER-2过表达乳腺癌中的疗效观察

doi: 10.3969/j.issn.1000-8179.20131484

深圳市第二人民医院甲乳外科（深圳市518035）

基金项目:

2012年深圳市科技计划项目 201202026

详细信息

作者简介:
陈伟财副主任医师，研究方向为乳腺癌外科治疗。E-mail：cwc0755@aliyun.com

通讯作者:
Xianming WANG; wxm60@yahoo.com.cn

计量
- 文章访问数: 101
- HTML全文浏览量: 11
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2013-09-23
- 修回日期: 2014-01-27
- 刊出日期: 2014-03-30

Efficacy observation of TCH/TAC neoadjuvant chemotherapy in treatment of HER-2 over-expressing breast cancer

Center for Breast Diseases Diagnosis and Treatment, the Second People's Hospital of Shenzhen, Shenzhen 518035, China

Funds:

Shenzhen Municipal Project of Scientific Planning 201202026

摘要

摘要: 目的观察TCH与TAC新辅助化疗方案在HER-2过表达乳腺癌的临床疗效。方法收集深圳市第二人民医院甲乳外科自2008年5月至2012年9月收治的64例HER-2过表达的乳腺癌患者，随机分为两组：TCH组39例，采用曲妥珠单抗联合多西他赛及卡铂治疗方案；TAC组25例，采用多西他赛、表阿霉素及环磷酰胺治疗方案。新辅助化疗6个周期后进行疗效对比。结果 TCH与TAC两组患者总有效率（OR）分别为94.9%（37/39）和72.0%（18/25），差异有统计学意义（P < 0.05）；病理完全缓解率（pCR）分别为69.2%（27/39）和32.0%（8/25），差异有统计学意义（P < 0.05）；两组患者在心功能障碍、骨髓抑制及肝功能损害等不良反应方面疗效均无显著性差异。结论在HER-2过表达乳腺癌的新辅助化疗中，多西他赛及卡铂联合曲妥珠单抗疗效良好，病理完全缓解率高。
- 乳腺癌 /
- 新辅助化疗 /
- HER-2 /
- 曲妥珠单抗
Abstract: Objective To observe the efficacy of neo-adjuvant chemotherapy with TCH and TAC regimens on the treatment of breast cancer caused by HER-2 over-expression. Methods A total of 64 HER-2 over-expression breast cancer patients were randomly divided into two groups. In the group treated with the TCH regimen, 39 patients underwent the Trastuzumab treatment combined with Docetaxel and Carboplatin. In the group treated with the TAC regimen, 25 patients underwent therapy using Docetaxel, Epirubicin, and Cyclophosphamide. Neo-adjuvant chemotherapy was continued for six cycles until a comparison of the therapeutic effects was made. Results The overall responses (OR) of patients in the two groups-TCG and TAC-were 94.9% (37/39) and 72% (18/25), respectively, P < 0.05. The pathologic complete responses (pCR) were 69.2% (27/39) and 32.0% (8/25), respectively, P < 0.05. No significant differences were observed between the two groups in terms of adverse reactions, such as cardiac dysfunction, bone marrow suppression, and liver function impairment. Conclusion During the treatment of HER-2 over-expressing breast cancer patients with neoadjuvant chemotherapy, Trastuzumab combined with Docetaxel and Carboplatin showed a favorable efficacy and a high pCR rate.
- breast cancer /
- neo-adjuvant chemotherapy /
- HER-2 /
- Trastuzumab

HTML全文

表 1 64例乳腺癌患者的临床一般资料

Table 1. Common clinical information of all patients

表 2 两组患者的OR及pCR对比

Table 2. Comparison of OR and pCR of two groups

参考文献(15)

[1]	左文述, 主编.现代乳腺肿瘤学(第2版)[M].济南:山东科学技术出版社, 2006: 1093-1094. Zuo WS. Modern breast oncology. Second edition[M]. Jinan: Shandong Science and Technology Press, 2006:1093-1094.
[2]	陈伟财, 何劲松, 宋淑芬, 等.乳腺癌ER, PR与HER-2, p53的表达及其相关性[J].中国普通外科杂志, 2010, 19(8):935-937. http://www.cnki.com.cn/Article/CJFDTotal-ZPWZ201008033.htm Chen WC, He JS, Song SF, et al. Expression of ER, PR and HER-2, p53 in breast cancer and their correlation[J]. Chin J Gen Surg, 2010, 19(8):935-937. http://www.cnki.com.cn/Article/CJFDTotal-ZPWZ201008033.htm
[3]	陈伟财, 何劲松, 王敏, 等.老年乳腺癌新辅助内分泌治疗的临床应用[J].中国癌症杂志, 2011, 21(5): 359-362. http://www.zhangqiaokeyan.com/academic-journal-cn_china-modern-doctor_thesis/0201255461033.html Chen WC, He JS, Wang M, et al. The clinical application of neoadjuvant endocrine therapy for the old patients with breast cancer[J]. Chin Oncol, 2011, 21(5):359-362. http://www.zhangqiaokeyan.com/academic-journal-cn_china-modern-doctor_thesis/0201255461033.html
[4]	杨莹, 魏兵, 步宏.乳腺癌HER2检测的现状及存在的问题[J].临床与实验病理学杂志, 2010, 26(5):602-605. http://www.cnki.com.cn/Article/CJFDTotal-LSBL201005033.htm Yang Y, Wei B, Bu H. HER2 status of breast cancer detection guidelines and problems[J]. Clin Exp Pathol, 2010, 26(5):602-605. http://www.cnki.com.cn/Article/CJFDTotal-LSBL201005033.htm
[5]	刘秋明, 曹亚丽, 吴晓波, 等.乳腺癌分子分型与多西他赛密集新辅助化疗疗效及预后的关系研究[J]中国全科医学, 2012, 15(36):4178-4182. http://www.cnki.com.cn/Article/CJFDTotal-QKYX201236010.htm Liu QM, Cao YL, Wu XB, et al. Relationship of molecular subtypes and therapeutic effect and prognosis of dose dense docetaxel neoadjuvant chemotherapy in breast cancer[J]. Chin General Practice, 2012, 15(36):4178-4182. http://www.cnki.com.cn/Article/CJFDTotal-QKYX201236010.htm
[6]	方志沂, 主编.乳腺癌[M].北京:北京大学医学出版社, 2007:246-254. Fang ZY. Breast Cancer[M]. Beijing: Peking University Medical Press, 2007:246-254.
[7]	黄冬凌.局部晚期乳腺癌的新辅助化疗TEC方案治疗观察[J].河北医学, 2012, 18(4):519-521. http://www.cqvip.com/QK/90263X/20124/41742653.html Huang DL. TEC program neoadjuvant chemotherapy for locally advanced breast cancer observed[J]. Hebei Med, 2012, 18(4): 519-521. http://www.cqvip.com/QK/90263X/20124/41742653.html
[8]	付强, 夏曙, 黎春蕾, 等.曲妥珠单抗辅助治疗26例HER2阳性乳腺癌患者长期心脏毒性观察[J].中国肿瘤临床, 2012, 39(23):1952-1955. http://www.cjco.cn/cn/article/doi/doi:10.3969/j.issn.1000-8179.2012.23.021 Fu Q, Xia S, Li CL, et al. Analysis of long-term cardiotoxicity of adjuvant trastuzumab therapy in HER2-positive breast cancer patients[J]. Chin J Clin Oncol, 2012, 39(23):1952-1955. http://www.cjco.cn/cn/article/doi/doi:10.3969/j.issn.1000-8179.2012.23.021
[9]	Lazaridis G, Pentheroudakis G, Pavlidis N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety[J]. Crit Rev Oncol Hematol, 2008, 66(1):31-41. http://www.sciencedirect.com/science/article/pii/S1040842807001576
[10]	Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J]. J Clin Oncol, 2005, 23(19):4265-4274. http://europepmc.org/abstract/MED/15911866
[11]	廖宁, 张国淳, 李学瑞, 等.联合曲妥珠单抗的新辅助化疗方案用于HER2阳性乳腺癌的Meta分析[J].南方医科大学学报, 2009, 2(5):943-945. http://www.cnki.com.cn/Article/CJFDTotal-DYJD200905032.htm Liao N, Zhang GC, Li XR, et al. A meta-analysis of neoadjuvent chemotherapy combined with trastuzumab for HER2-positive breast cancer[J]. South Med Unive, 2009, 2(5):943-945. http://www.cnki.com.cn/Article/CJFDTotal-DYJD200905032.htm
[12]	Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis[J]. J Natl Cancer Inst, 2005, 97(3):188-194. http://europepmc.org/abstract/MED/15928308
[13]	许玲辉, 顾雅佳.乳腺磁共振在乳腺癌诊断治疗中的运用[J].中国癌症杂志, 2013, 23(8):613-617. http://d.wanfangdata.com.cn/Periodical/zgazzz201308013 Xu LH, Gu YJ. Application and evaluation of magnetic resonance imaging in the multidisciplinary treatment of breast cancer[J]. China Oncology, 2013, 23(8):613-617. http://d.wanfangdata.com.cn/Periodical/zgazzz201308013
[14]	段丹丹.曲妥珠单抗的不良反应及处理[J].中国现代医药杂志, 2011, 13(8):128-131. http://www.cqvip.com/QK/83747X/20036/8881347.html Duan DD. Adverse reactions of trastuzumab and its treatment[J]. MMJC, 2011, 13(8):128-131. http://www.cqvip.com/QK/83747X/20036/8881347.html
[15]	Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts[J]. Cancer Res, 1998, 58(13): 2825-2831. http://www.tandfonline.com/servlet/linkout?suffix=CIT0019&dbid=8&doi=10.3109%2F07357900009012176&key=9661897